1213036-86-2 Usage
General Description
"(2S)-2-(4-fluoro-2-methylphenyl)pyrrolidine" is a chemical compound with a molecular formula of C11H14FN. It is a pyrrolidine derivative, which is a type of organic compound containing a five-membered ring with one nitrogen atom. This particular compound has a molecular weight of 181.23 g/mol. The "2S" in its name indicates that it is the (S)-enantiomer, meaning it has a specific arrangement of atoms that gives it a chiral, or mirror-image, structure. The presence of a fluorine atom and a methyl group in the phenyl ring of the pyrrolidine structure gives this compound unique properties that may be useful in various research and industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1213036-86-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,3,0,3 and 6 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1213036-86:
(9*1)+(8*2)+(7*1)+(6*3)+(5*0)+(4*3)+(3*6)+(2*8)+(1*6)=102
102 % 10 = 2
So 1213036-86-2 is a valid CAS Registry Number.
1213036-86-2Relevant articles and documents
A class of histone acetylase p300 inhibitors, and application thereof
-
Paragraph 0168-0169; 0176-0178; 0828-0829; 0836-0838, (2020/06/17)
The invention discloses a class of histone acetylase p300 inhibitors, and application thereof, and belongs to the technical field of medicinal chemistry. The invention discloses a compound representedby a formula (I), or a stereochemical isomer, a solvate or a pharmaceutically acceptable salt thereof. According to the invention, the compound can effectively inhibit the activity of histone acetylase p300 and can effectively inhibit the proliferation activity of various tumor cells; the compound is combined with a CDK4/6 inhibitor to play a synergistic role in inhibiting proliferation of tumorcells; and the compound has good application prospects in preparation of histone acetylase inhibitors, preparation of drugs for preventing and/or treating cancers, metabolic diseases, neurological diseases or inflammations, and combination of drugs.
